Reports
Precision Psychiatry Market Business Trends, Strategies, and Forecasts, 2025-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Market Statistics
What is the precision psychiatry market size?
The global precision psychiatry market size was valued at USD 842.22 million in 2024, growing at a CAGR of 14.5% from 2025 to 2034. Precision psychiatry innovation is driven by growing awareness about mental health and increasing research funding.
Key Insights
- The products segment dominated the precision psychiatry market in 2024.
- The segment of pharmaceutical and biotechnology companies is growing the fastest owing to increasing biomarker-based drug development.
- The largest market share was held by North America in 2024.
- The U.S. market is driven by strong neurogenomic research and AI-based diagnostics.
- Asia Pacific is expanding rapidly with growing awareness of mental health and genomic research.
- China and India are driving regional growth through government funding and precision psychiatry adoption.
Industry Dynamics
- Increasing mental health awareness promotes the use of precision-based psychiatric solutions.
- Increasing government funding for neuroscience and genomics research accelerates innovation in precision psychiatry.
- The integration of AI and data analytics is enhancing diagnostic precision, and personalization of treatment.
- High prices of genomic testing and its limited clinical validation are hindering large-scale adoption.
Market Statistics
- 2024 Market Size: USD 842.22 Million
- 2034 Projected Market Size: USD 3,254.83 Million
- CAGR (2025–2034): 14.5%
- North America: Largest Market Share
What is precision psychiatry market?
Precision psychiatry includes tools and platforms that help identify biomarkers, genetic variants, and neural patterns of psychiatric disorders. These tools are then used in pharmaceutical, biotechnology companies, and clinical research to facilitate the diagnosis and treatment of the disease. Development of AI-driven analytics and genomic profiling is a key strategy for companies to improve precision and results of therapies.
The growing awareness of mental health is driving the adoption of precision-based psychiatric solutions. Increasing government participation in neuroscience and genomics research accelerates innovation across diagnostic and treatment applications. Improvement in computational models and biomarker validation increases reliability in clinical decision-making.
Moreover, high costs associated with genomic testing, together with a lack of standardized biomarkers, are holding the wider diffusion of tests. Continuous innovation in AI-based diagnostic tools, digital health platforms, and companion diagnostics creates new growth opportunities both in research and clinical psychiatry segments. For instance, in October 2025, NetraMark Holdings Inc., presented AI-driven advances in precision psychiatry at a big conference to enhance clinical trial design and patient stratification.
Drivers & Opportunities
Which are the factors driving precision psychiatry market growth?
Rising Mental Disorder Driving Adoption of Precision Care Models: Rising global mental health issues is driving greater acceptance of precision-based care models. World Health Organization (WHO) stated that over 1 billion people suffer from mental health disorders, with depression and anxiety costing the global economy about USD 1 trillion annually. Increasing patient focus on accurate diagnosis and personalized treatment is encouraging healthcare providers to adopt genomic and biomarker-driven approaches. This shift is supporting early detection, targeted interventions, and improved patient outcomes across psychiatric disorders.
Government Funding Accelerating Innovation in Neuroscience and Genomics Research: Increasing government funding of neuroscience and genomics research is accelerating innovation in precision psychiatry. Government initiatives to study the brain, integrate data, and clinically translate findings increase access to novel diagnostic technologies. Such investments are enabling with the development of biomarker-based tools and digital platforms that can further increase precision in treatment and effectiveness.
Segmental Insights
Product Type Analysis
By product type, the market is divided into products and services. The products segment led the segment in 2024 due to growing adoption of genomic and biomarker testing tools. Moreover, rising use of precision diagnostic kits across healthcare and research institutions supported steady product demand.
The services segment is projected to grow at the fastest pace, driven by rising outsourcing of genomic and biomarker analysis. In addition, expanding collaborations between diagnostic firms and research centers are supporting segment growth.
Sample Analysis
Based on sample, the market is segmented into blood-based and non-blood-based. The blood-based segment dominated the market in 2024, supported by its ease of collection and strong reliability in biomarker detection. Moreover, its widespread use in genomic and proteomic screening strengthened its position.
The non-blood-based segment is projected to grow at the fastest pace, driven by increasing use of cerebrospinal and saliva-based samples. In addition, advancements in neuroimaging and multi-omics tools are expanding its diagnostic utility.
Biomarker Type Analysis
Based on biomarker type, the market is segmented into genetic biomarker and protein biomarker. The genetic biomarker segment dominated the market in 2024, driven by growing research on gene variants linked to psychiatric disorders. Moreover, rising use of sequencing for early genetic risk detection boosted its growth.
The protein biomarker segment is expected to grow at the fastest pace, driven by increasing proteomic profiling in mental health research. In addition, protein-based indicators for treatment monitoring are gaining research interest.
Technology Analysis
By technology, the market is divided into sequencing, polymerase chain reaction (PCR), microarray, immunoassay, liquid chromatography-mass spectrometry (LC-MS), and others. The sequencing segment dominated the market in 2024, driven by rising use of next-generation sequencing for psychiatric biomarker discovery. Moreover, declining sequencing costs are promoting wider adoption in research and clinics.
The polymerase chain reaction (PCR) segment is projected to grow at the fastest pace, supported by its high sensitivity in biomarker quantification. In addition, continuous advancements in qPCR and digital PCR platforms are improving accuracy.
Application Analysis
Based on application, the market is segmented into Alzheimer’s disease, Parkinson’s disease, autism, depression, bipolar disease, and others. The Alzheimer’s disease segment dominated in 2024 due to rising biomarker research and growing neuroimaging adoption. Moreover, increasing clinical studies on early detection and targeted therapy supported its dominance.
The depression segment is projected to grow fastest, driven by expanding genomic research and AI-based diagnostics. In addition, rising mental health awareness is supporting precision-based treatment adoption. In October 2025, NeuroKaire has entered an R&D collaboration with Compass Pathways to use AI-based neural models and patient-derived neurons to pioneer precision treatments for depression.
End User Analysis
Based on end user, the market is segmented into hospitals and diagnostic laboratories, academic and research institutions, and others. The hospitals and diagnostic laboratories dominated in 2024 due to higher patient volume and growing genomic testing adoption. Moreover, integration of precision diagnostics in clinical workflows strengthened this segment.
The academic and research institutions are expected to grow fastest, supported by rising neurogenomics funding and research collaborations. In addition, advanced data analytics adoption is improving research outcomes.
Regional Analysis
North America dominated the precision psychiatry market in 2024, fueled by strong investment in neurogenomics and AI-based diagnostic platforms. Moreover, increasing adoption of personalized mental health programs across the US is supporting precision-based treatment development and clinical integration.
The U.S. Precision Psychiatry Market Insights
The U.S. held the highest market share in North America due to high R&D funding for mental health genomics and biomarker discovery. In addition, the presence of major biotech firms and academic consortia is accelerating translation into clinical practice. For example, in September 2025, Precision Psychiatry now offers a new, non-invasive device for brain stimulation to treat depression and support both mental and physical health.
Europe Precision Psychiatry Market Assessments
Europe is anticipated to contribute a major share due to increasing research activities for psychiatric biomarker validation and genetic testing. In addition, the increase in government investments in digital mental health infrastructure is giving better access to diagnostics informed by data and personalized therapeutic approaches.
Asia Pacific Precision Psychiatry Market Trends
Asia Pacific is expected to grow at the fastest CAGR during the forecast period due to increasing awareness about mental health and rapidly expanding genomics research hubs across China, Japan, and India. In April 2025, Fortis Healthcare launched a Genomic Medicine Institute in order to expand precision medicine using genomics and AI across major specialties.
China Precision Psychiatry Market Overview
The China market is growing at a rapid pace, propelled by government-backed precision medicine initiatives and investments in mental health R&D. Furthermore, the expansion of genome sequencing facilities and AI-based health startups is accelerating technology adoption in psychiatric research.
Key Players & Competitive Analysis
The precision psychiatry market is very competitive, involving efforts by companies to use AI-driven diagnosis and biomarker discovery for the enhancement of precision in treatment. Additionally, collaborations among biotech firms, research institutes, and healthcare providers are accelerating innovation and widening regional market presence.
Who are the major players in precision psychiatry market?
Some of the major firms in the precision psychiatry sector are Boehringer Ingelheim International GmbH, Alto Neuroscience Inc., Altimate Healthcare, Feel Therapeutics, Tempus, HMNC Holding GmbH, Spring Care, Inc., Mobio Interactive, NeuroKaire, Illumina, Inc., Otsuka Precision Health, Inc., Genomind, and Atai Life Sciences N.V.
Key Players
- Alto Neuroscience Inc.
- Altimate Healthcare
- Atai Life Sciences N.V.
- Boehringer Ingelheim International GmbH
- Feel Therapeutics
- Genomind
- HMNC Holding GmbH
- Illumina, Inc.
- Mobio Interactive
- NeuroKaire
- Otsuka Precision Health, Inc.
- Spring Care, Inc.
- Tempus
Precision Psychiatry Industry Developments
July 2025: NIMHANS and the University of Oslo launched the PrecInNor initiative for the development of precision psychiatry through integrated research in genetics, imaging, and data science.
May 2025: Alto Neuroscience is pushing four Phase 2 trials employing precision psychiatry methods, including patient stratification with biomarkers to better match treatments in unmet psychiatric areas.
April 2025: Johnson & Johnson Impact Ventures invested in Mobio Interactive to scale "precision psychiatry" tools for both patients and healthcare workers around the world.
April 2023: Columbia University launched a centre worth USD 75 million to further precision psychiatry and mental health research.
Precision Psychiatry Market Segmentation
By Product Type Outlook (Revenue, USD Million, 2020–2034)
- Products
- Services
By Sample Outlook (Revenue, USD Million, 2020–2034)
- Blood-Based
- Non-Blood-Based
- Saliva
- Urine
- Cerebral Spinal Fluid (CSF)
- Others
By Biomarker Type Outlook (Revenue, USD Million, 2020–2034)
- Genetic Biomarker
- Protein Biomarker
By Technology Outlook (Revenue, USD Million, 2020–2034)
- Sequencing
- Next-Generation Sequencing (NGS)
- Sanger Sequencing
- Polymerase Chain Reaction (PCR)
- Real-Time Polymerase Chain Reaction (RT-PCR)
- Digital Polymerase Chain Reaction (dPCR)
- Microarray
- Immunoassay
- Liquid Chromatography-Mass Spectrometry (LC-MS)
- Others
By Application Outlook (Revenue, USD Million, 2020–2034)
- Alzheimer’s Disease
- Parkinson’s Disease
- Autism
- Depression
- Bipolar Disease
- Others
By End User Outlook (Revenue, USD Million, 2020–2034)
- Hospitals and Diagnostic Laboratories
- Academic and Research Institutions
- Others
By Regional Outlook (Revenue, USD Million, 2020–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Precision Psychiatry Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | USD 842.22 Million |
| Market Size in 2025 | USD 962.23 Million |
| Revenue Forecast by 2034 | USD 3,254.83 Million |
| CAGR | 14.5% from 2025 to 2034 |
| Base Year | 2024 |
| Historical Data | 2020–2023 |
| Forecast Period | 2025–2034 |
| Quantitative Units | Revenue in USD Million and CAGR from 2025 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 842.22 million in 2024 and is projected to grow to USD 3,254.83 million by 2034.
The global market is projected to register a CAGR of 4.5% during the forecast period.
North America led in 2024, driven by advanced neurogenomic research infrastructure and strong investment in precision psychiatry programs.
A few of the key players in the market are Boehringer Ingelheim International GmbH, Alto Neuroscience Inc., Altimate Healthcare, Feel Therapeutics, Tempus, HMNC Holding GmbH, Spring Care, Inc., Mobio Interactive, NeuroKaire, Illumina, Inc., Otsuka Precision Health, Inc., Genomind, and Atai Life Sciences N.V.
The products segment dominated due to increasing adoption of genomic and biomarker testing tools across research and clinical settings.
Pharmaceutical and biotechnology companies are projected to grow fastest with expanding biomarker-based drug development initiatives.
Download Sample Report of Precision Psychiatry Market
Please fill out the form to request a customized copy of the research report.
